期刊文献+

吡柔比星与卡介苗交替灌注预防浅表性膀胱癌术后复发的疗效观察 被引量:4

Curative Effect Observation of Preventing Bladder Carcinoma Recidivation after Operati on by Perfusing Pirarubicin and Bacille Calmette Guerin in Turn
暂未订购
导出
摘要 目的观察吡柔比星(THP)与卡介苗(BCG)交替灌注的化学免疫疗法预防浅表性膀胱癌术后复发的疗效。方法将128例行经尿道膀胱癌电切术的浅表性膀胱癌患者,随机分为3组:Ⅰ组行THP与BCG交替灌注(48例)、Ⅱ组行THP灌注(40例)、Ⅲ组行BCG灌注(40例),随访5年,比较三组肿瘤复发率。结果随访18月5年,平均4.2年,三组患者复发率分别为8.3%(4/48)、17.5%(7/40)和20%(8/40),Ⅱ、Ⅲ组比较差异无统计学意义(P〉0.05),Ⅰ组复发率低于Ⅱ、Ⅲ组(P〈0.05)。结论吡柔比星与卡介苗交替灌注的化学免疫疗法明显降低了浅表性膀胱癌的术后复发率,优于单用化疗药物或免疫制剂。 Objective To observe the effect of preventing bladder carcinoma recidivation after surgical operation by perfusing pirarubicin and bacille calmette guerin in turn.Methods A total of 128 patients with bladder carcinoma after TUR-Bt were divided into three groups at random,i.e.Group A(perfusing pirarubicin and bacille calmette guerin in turn),Group B(perfusing pirarubicin) and Group C(perfusing bacille calmette guerin).Their relapse rates in five years were compared.Results After 18 months to 5 years' follow-up visit(4.2 years in average),it was founded that the relapse rates were 8.3%(4/48),17.5%(7/40) and 20%(8/40) respectively in Group A,Group B and Group C.The relapse rate of Group A was lower than that of Group B or Group C(P〈0.05).Conclusion The chemoimmunotherapy of preventing bladder carcinoma recidivation by perfusing pirarubicin and bacille calmette guerin in turn is better than chemotherapeutics or immunotherapy alone.
出处 《临床军医杂志》 CAS 2009年第6期988-989,共2页 Clinical Journal of Medical Officers
关键词 浅表性膀胱癌 吡柔比星 卡介苗 膀胱灌注 bladder neoplasm pirarubicin bacille calmette guerin bladder irrigation
  • 相关文献

参考文献5

二级参考文献23

共引文献1471

同被引文献40

  • 1兰卫华,靳风烁,王洛夫,张军,孙中义,谢芳.卡介苗与丝裂霉素C膀胱灌注预防国人膀胱癌复发的比较的Meta分析[J].临床泌尿外科杂志,2006,21(2):145-148. 被引量:10
  • 2刘锁民,刘屹立.丝裂霉素与卡介苗联合灌注预防表浅膀胱癌术后复发的疗效观察[J].中国厂矿医学,2007,20(3):205-206. 被引量:4
  • 3方文杰,毕满华,江鉴平,金能成.卡介苗加丝裂霉素膀胱灌注预防膀胱癌术后复发的疗效[J].安徽医学,2007,28(3):221-222. 被引量:2
  • 4Mochizuki Y, Matsushima E, Omura K. Perioperative assessment of psychological state and quality of life of head and neck cancer patients undergoing surgery[J]. Int J Oral Maxillofac Surg. 2009,38(2) :151-159.
  • 5Nepple KG, Lightfoot A J, Rosevear HM, et al. Bacillus Calmette- Guerin with or without interferon α-2b and megadose versus rec- ommended daily allowance vitamins during induction and mainte- nance intravesical treatment of nonmuscle invasive bladder cancer [ J]. Urology ,2010,184 ( 5 ) : 1915 - 1919.
  • 6Liu W, O' Donnell MA, Chen X, et al. Recombinant Bacillus Calmette-Gu6rin (BCG) expressing interferon-alpha 2b en- hances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro [ J ]. Cancer Immunol Immunother, 2009,58(10) :1647 - 1655.
  • 7那彦群;孙则禹;叶章群.中国泌尿外科疾病诊断治疗指南2007[M]北京:人民卫生出版社,2007104-105.
  • 8Nieder AM,Simon MA,Kim SS. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta,T1,and carcinoma in situ:defining the risk of initial bladder preservation[J].Urology,2006,(04):737-741.
  • 9Witjes JA,Hendricksen K. Intravesical pharmacotherapy for non muscle-invasive bladder cancer:a critical analysis of currently available drugs,treatment schedules,and long-term results[J].European Urology,2008,(01):45-52.
  • 10Shelley MD,Jones G,Cleves A. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC):a systematic review[J].British Journal of Urology International,2012,(04):496-505.

引证文献4

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部